globenewswire news

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-07-08T20:05:00Z

ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

Attachment

Notification of managers' transaction - Riad Sherif - 5 July 2026 RSU vest

Articles

Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity

2026-07-08T21:07:01Z

BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today...

Range Impact Announces Vin Ferrara, MD, MBA, Has Joined the Company as Vice President, Real Estate

2026-07-08T20:15:00Z

CLEVELAND, OHIO, July 08, 2026 (GLOBE NEWSWIRE) -- Range Impact, Inc. (OTC: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing former industrial and...

UPDATE: Endogenex Announces Full Enrollment of the ReCET Clinical Study

2026-07-08T20:10:36Z

350 Patients Enrolled Across Sites in the United States and Australia, Advancing the Path to FDA Approval of a Novel Endoscopic Treatment for Type 2 Diabetes

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-07-08T20:05:00Z

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes...

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

2026-07-08T20:05:00Z

ZUG, Switzerland, July 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a director of the Company.

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

2026-07-08T20:05:00Z

SAN DIEGO, July 08, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a biotechnology company pioneering the development of targeted genetic medicine, today announced that in connection...

Vaxcyte to Participate in Upcoming Investor Conferences

2026-07-08T20:05:00Z

SAN CARLOS, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in and host one-on-one meetings...

BrightSpring Health Services, Inc. to Announce Second Quarter 2026 Financial Results on July 31, 2026

2026-07-08T20:05:00Z

LOUISVILLE, Ky., July 08, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG) announced today that it plans to release its second quarter 2026 financial...

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

2026-07-08T20:05:00Z

IRX-101 targets a significant need for millions of patients facing vision loss and has the potential to improve the standard of care

Cosmos Health Share Buyback Surpasses 4 Million Shares; Continues Open Market Repurchases

2026-07-08T19:40:00Z

CHICAGO, July 08, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an...

Cascade Prodrug and Uneedle Advance Collaboration to Enable Suprachoroidal Delivery of CPD100 for Wet AMD

2026-07-08T18:00:00Z

PORTLAND, Ore. and ENSCHEDE, The Netherlands, July 08, 2026 (GLOBE NEWSWIRE) -- Cascade Prodrug Inc. and Uneedle are advancing their collaboration to evaluate CPD100, Cascade’s first-in-class hypoxia-targeted therapeutic, in neovascular,...

SRX Global Reports Preliminary Net Asset Value of Approximately $3.07 Per Share and Over $55 Million in Cash and Short-Term Investments(1)

2026-07-08T17:46:54Z

Approximately $40 million in cash and more than $15 million in short-term investment assets as of June 30, 20261

Sienna Announces Second Quarter 2026 Results Release Date and Conference Call

2026-07-08T16:17:49Z

MARKHAM, Ontario, July 08, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced that it will report its 2026 second quarter results after market...

Half-Year Report on Liquidity Contract with Invest Securities

2026-07-08T16:00:00Z

NANTES, France, July 8, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) – Under the liquidity contract entrusted by OSE Immunotherapeutics to Invest Securities, the following resources...

Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

2026-07-08T16:00:00Z

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), July 8, 2026 - GENFIT (Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver...

Cerene® Cryotherapy Announces Know Your Flow Event Series To Empower Women Through Free Menstrual and Perimenopause Education

2026-07-08T14:06:23Z

The First Two Events Will Take Place in New York and Charlotte

As America Celebrates its 250th Birthday, Becoming Independent Marks 59 Years of Helping People Live on Their Own Terms

2026-07-08T14:00:00Z

Becoming Independent Named No. 17 on “The NonProfit Times' 2026 Best Nonprofits To Work For”

MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

2026-07-08T13:45:00Z

90.5% interim disease control rate (DCR) observed with combination therapy

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

2026-07-08T13:15:00Z

The appointment follows NewcelX's recently announced successful FDA Type B Pre-IND meeting for NCEL-101, providing a clear regulatory pathway toward clinical trials

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

2026-07-08T13:08:18Z

NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2025 Impact Report, detailing the company's work on behalf of patients and families living with...

Tekton Research and Summit Clinical Research Solutions Expand Partnership, Bring MASH Trials to Ohio

2026-07-08T13:05:00Z

NEW CARLISLE, Ohio, July 08, 2026 (GLOBE NEWSWIRE) -- Tekton Research, a multi-specialty clinical research site organization, is expanding its partnership with Summit Clinical Research Solutions (“Summit”). Under the supervision...